Physician profile
David Kayne
NPI 1144334533
$843,455.48
in general payments reported to CMS, 2019-2025
42 companies · $93K in 2025
The $93K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $79K · 2021: $137K · 2022: $171K · 2023: $111K · 2024: $96K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $40K · Travel and Lodging: $35K · Consulting Fee: $22K · Honoraria: $20K · Food and Beverage: $15K · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,389.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $40,002.00 |
| Travel and Lodging | $34,655.74 |
| Consulting Fee | $22,229.50 |
| Honoraria | $19,980.00 |
| Food and Beverage | $15,145.70 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $367,258.28 | 2019-2025 | Mounjaro, Trulicity |
| Novo Nordisk INC | $183,734.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $87,297.38 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $44,408.86 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $39,773.80 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $26,617.48 | 2019-2022 | |
| Mannkind Corporation | $23,663.27 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $22,029.57 | 2019-2024 | |
| Insulet Corporation | $19,530.95 | 2019-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals LP | $14,193.43 | 2019-2024 | Farxiga, Breztri |
| Abbott Laboratories | $2,922.08 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Medtronic, INC. | $2,545.55 | 2021-2025 | Minimed 780g |
| Eli Lilly and Company | $1,687.50 | 2025 | |
| Novo Nordisk As | $1,444.64 | 2019 | |
| Senseonics, Incorporated | $965.00 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $689.67 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $594.75 | 2024 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $565.70 | 2022-2025 | |
| Amgen INC. | $470.10 | 2019-2025 | Evenity, Repatha |
| Amarin Pharma, INC. | $422.09 | 2019-2021 | |
| Medtronic Minimed, INC. | $387.63 | 2019-2020 | |
| Sequel Med Tech, LLC | $363.87 | 2025 | Twiist |
| Corcept Therapeutics | $322.31 | 2019-2025 | Korlym |
| Beta Bionics, INC. | $271.23 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $192.95 | 2019-2021 | |
| Intuitive Surgical, INC. | $145.43 | 2020 | |
| Abbvie INC. | $142.70 | 2021-2023 | |
| Exact Sciences Corporation | $122.07 | 2025 | The Cologuard Plus Collection Kit |
| Lexicon Pharmaceuticals, INC. | $118.71 | 2024 | Inpefa |
| Glaxosmithkline, LLC. | $113.86 | 2023 | Arexvy |
| Companion Medical, INC. | $105.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.53 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $80.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.44 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.03 | 2025 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $30.67 | 2019 | |
| Daiichi Sankyo INC. | $23.90 | 2019 | |
| Lifescan, INC. | $19.95 | 2020 | |
| Zealand Pharma US, INC. | $17.89 | 2020 | |
| Genentech USA, INC. | $14.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $8.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.